CiToxLAB has acquired Canadian contract research organization (CRO) AccelLAB, which is specialized in the pre-clinical assessment of new medical devices.
Established in 2004, AccelLAB provides services for medical devices and biotechnology industry, specializing in the fields of cardiology and orthopedics.
With around 100 employees, the company operates facilities with 40,000ft² of space and features modern technologies for the fields of surgery and medical imaging such as scanning and MRI.
AccelLAB’s facilities include operating rooms for cardiac catheterization, modern laboratories, large vivarium medical imaging department (scanning and MRI) and clinical pathology and histopathology laboratories
The acquisition will allow CiToxLAB to expand its services portfolio to medical devices and reinforce its position in the non-clinical CRO arena.
CiToxLAB chairman and CEO Dr. Jean-François Le Bigot said: “We identified AccelLAB as a strategic target to make our group a more global services player in the Life Sciences Services arena.
“Within CiToxLAB Group, AccelLAB allows the convergence process between the development of new drugs and medical devices which represents a new offer to the customers in particular in the cardiovascular, orthopedic fields and more generally in the regenerative medicine.”
AccelLAB chairman and CEO Dr Guy Leclerc said: “CiToxLAB has large capacities in histology, pathology, bioanalysis and biomarkers, which are of interest for us, when we have several platforms of imaging of interest for them “.
With six facilities in France, Canada, Denmark and Hungary, CiToxLAB provides a range of preclinical services to the pharmaceutical, biotechnology, medical device and chemical companies across the globe.
Image: CiToxLAB has acquired medical device CRO AccelLAB. Photo: courtesy of stockimages / FreeDigitalPhotos.net.